2016 Leads Prescription 
World of DTC Marketing
JUNE 18, 2021
This report is going to lead to more calls to limit DTC advertising. 1ne: Medicare Parts B and D and beneficiaries spent $560 billion on drugs from 2016 through 2018, $324 billion spent on advertised drugs. Do DTC ads lead to increased patient knowledge of chronic health issues? So let’s look at the contents.
World of DTC Marketing
SEPTEMBER 7, 2022
In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. According to JAMA , “in a cross-sectional study, between May 1, 2016, and May 31, 2021, there were 207 cancer drug approvals in oncology and malignant hematology. ” The U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Legacy MEDSearch
MARCH 15, 2023
Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.
European Pharmaceutical Review
JULY 4, 2024
1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 3 Is two too few? 2012/1916).
pharmaphorum
AUGUST 11, 2022
More than 60 percent of all American adults take prescription drugs , amounting to approximately 131 million individuals. In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 billion in the United States alone.
Pharmaceutical Technology
SEPTEMBER 23, 2022
Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products. Competing against Restasis are Novartis’ Xiidra (lifitegrast ophthalmic solution 5%), which launched in the US in 2016, and Sun Pharma’s Cequa (cyclosporine ophthalmic solution 0.09%), which launched in the US in 2019.
Clarify Health
MARCH 1, 2023
Placing clinicians at financial risk for controlling health costs and improving quality without equipping them with the tools to do so leads to frustration and disillusionment. There was a significant decrease in pills per prescription both for peer comparison feedback and for the combination of peer comparison and individual audit feedback.
Expert insights. Personalized for you.
187 
Let's personalize your content